ARCT vs DERM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ARCT exhibits severe financial distress despite a modest insider sentiment score and analyst buy consensus. The Piotroski F-Score of 0/9 signals extreme financial weakness, with no positive indicators in profitability, cash flow, or leverage management. The Altman Z-Score is unavailable, but the company's negative margins, declining revenue, and negative earnings suggest high distress risk. While the stock trades below its 52-week high, its 5-year decline of 87.2% and persistent losses underscore deep operational challenges. The Graham Number and intrinsic value are unavailable, indicating no reliable fundamental floor, and the current price reflects speculative expectations rather than sustainable value.
DERM shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 0/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
ARCT vs DERM: Head-to-Head Comparison
This page compares Arcturus Therapeutics Holdings Inc. (ARCT) and Journey Medical Corporation (DERM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.